Betalin Therapeutics

Liberating from Insulin Dependency

Jerusalem, Israel · Founded 2015 · $8.1M raised

Headquarters
Jerusalem
Founded
2015
Business Model
B2B
Total Funding
$8.1M
Last Round
$565K Series AJan 2022
Rounds
4

About

Betalin Therapeutics is developing a bio-engineered micro-pancreas (EMP) that combines stem-cell-derived insulin-producing cells with a supportive tissue scaffold (micro-organ matrix) to treat diabetes via a single subcutaneous transplant. Licensed from the Hebrew University in 2015 and led by CEO Racheli Ofir, the Israel-based biotech aims to eliminate the lifelong immune suppression and low engraftment rates seen with conventional islet-cell transplants.

Summary

Betalin Therapeutics is a Biotech company based in Jerusalem, Israel, founded in 2015. It has raised $8.1M in total across 4 rounds, most recently a $565K Series A round in Jan 2022. Investors include European Innovation Council Fund and Horizon 2020.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AJan 2022
$565K

Sign up to see all 4 rounds

Grant through Series A — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Betalin Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/betalin-therapeutics"><img src="https://indexed.vc/api/badge/company/betalin-therapeutics" alt="Betalin Therapeutics on Indexed.vc" width="260" height="76" /></a>